Eyestem files for IND approval for its product to treat geographic atrophy, the largest cause of incurable blindness in the world for people over 50

Bengaluru (Karnataka) [India], June 5: Dry age-related macular degeneration (dry AMD) is the largest cause of incurable blindness in the world for patients over 50 years. 170 million people suffer from this disease around the world, 25 million of which are in India. These numbers will, unfortunately, increase in the coming decades as our population ages. The more severe version of dry AMD is geographic atrophy, and no therapy is available to arrest or reverse this loss of vision.

Eyestem Research today announced the submission of an Investigational New Drug (IND) application to the Central Drugs Standards Control Organization, India (CDSCO) to begin first-in-human trials of Eyecyte-RPEfor subjects with medium- and late-stage geographic atrophy, secondary to dry AMD.

Dr. Rajani Battu, Chief Medical Officer of Eyestem Research, said, “We are excited to start human trials for Eyecyte-RPE. Dry AMD is a huge disease burden, and this therapy has the potential to make a meaningful difference in our patient’s lives.”

Dr. Jogin Desai, Chief Executive Officer of Eyestem Research, said, “Most cell and gene therapy products under development in the West are estimated to cost over US$ 200,000.Our vision is to democratize access to such treatments at a fraction of these costs and begin disruption of the current status quo with our Eyecyte-RPE product.”

Eyestem Research is a deep science company incubated at the Centre for Cellular and Molecular Platforms, Bangalore, and supported by DBT-BIRAC as well as prestigious Indian and global healthcare investors. The IND submission for Eyecyte-RPEis supported by robust GLP toxicology data from Dabur Research Foundation in India and excellent efficacy/safety data in animal models at Oregon Health and Science University. Validation of the injection technique and dose-finding studies were done in advanced animal models at the Singapore Eye Research Institute.

About Eyecyte-RPE

Eyecyte-RPE™ is a patented suspension of iPSC-derived fate-committed retinal pigment epithelium cells, which are highly potent, safe, and efficacious in in-vitro and in-vivo studies. The cells are derived from induced pluripotent stem cells, are allogeneic in nature, and can be stored for long periods of time.

If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

The post Eyestem files for IND approval for its product to treat geographic atrophy, the largest cause of incurable blindness in the world for people over 50 first appeared on PNN Digital.

Advanced APTOS Anti-Ageing American Doctors Business News Health PNN News Press Release Sakhiya Skin Clinic

Surat’s Sakhiya Skin Clinic Hosts First-Ever Live Training on Advanced APTOS Anti-Ageing Method by American Doctors

Surat (Gujarat) [India], June 13:  In a first time for Gujarat, a team of American doctors conducted a live training session on APTOS Method, an advanced anti-ageing treatment, for the specialists at Sakhiya Skin Clinic in Surat. The training took place on May 26 at the clinic’s Lal Darwaza location, led by Dr. Lakshyajeet Dhami […]

Read More
Business News Dr. Ekta Vala Chandarana Health mammography screenings Medical Oncologist PNN News Press Release rising incidence of breast cancer in India

Dr. Ekta Vala Chandarana And AOGS Lead the Charge in Breast Cancer Awareness with “Impact” Series

Ahmedabad (Gujarat) [India], June 11:  In a significant step towards combating breast cancer in India, Dr. Ekta Vala Chandarana, Medical Oncologist in collaboration with the Ahmedabad Obstetrics and Gynaecological Society (AOGS), hosted the inaugural session of the “Impact” series. This landmark event brought together top oncologists and medical professionals from across Ahmedabad, Gujarat to discuss the alarming […]

Read More